SLCO1B3 and non-small cell lung carcinoma: Docetaxel is approved for the treatment of CRPC and non-small cell lung cancer (NSCLC) and OATP1B3 is highly expressed in both prostate and lung tumors suggesting that the effectiveness of docetaxel treatment in these diseases may be, in part, due to sensitivity to docetaxel resulting from the underlying disease etiology.